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CHOLINERGIC HYPOTHESIS & STEM CELL TREATMENT I GAUTAM & NICHOLS 
Alzheimer's - The Cholinergic Hypothesis and Gene — Targeting Stem 
Cell Treatment 
Richa Gautam and Emma Nichols 
Vassar College 
As the mean age of the world population rises and people's life expectancies increase, the prevalence ofAlzheimer's 
disease will increase and will pose a threat to society in terms of the people affected and the money used. Current 
therapies are not adequate in that they are unable to extend life beyond a few months. This review will both 
overview the predominant hypotheses about how to approach the treatment ofAlzheimer's as well as discuss some of 
the treatments available and those in preclinical phases. Finally, we will discuss the ideas and recent research behind 
gene therapy and stem cell therapy as well as the new ways in which these two methods have been combined and 
could be combined in the future to create a more effective approach to treating Alzheimer's. 
Alzheimer's disease is the most common 
neurodegenerative disorder worldwide (Jakob-
Roetne & Jacobsen, 2009). As it is most 
frequent in old age, the changing population 
demographics lead to concerns regarding the 
occurrence rate and lack of a cure. 
Alzheimer's is a type of dementia and normally 
presents symptoms of memory loss and ability 
to learn and reason. This can cause patients to 
lose understanding of who they are, who others 
are and where they are, causing panic and 
distress (Chen & Blurton-Jones, 2012). This 
creates many problems for Alzheimer's 
patients and their loved ones and these issues 
have prompted much research in the field of 
Alzheimer's disease over the past few decades. 
Amyloid Hypothesis 
Much of the research regarding Alzheimer's 
has focused on the workings and implications 
of the amyloid hypothesis. The hypothesis 
posits that the accumulation of the amyloid-
beta peptide (A13) in the central nervous system 
(CNS) triggers a cascade of events that leads to 
cell death. The series of events that leads to the 
excess Ai3 begins with the 13-amyloid precursor 
protein, which occurs in different variants, all 
of which can be spliced into different versions 
of A13 (Jakob-Roetne et al., 2009). Although 
A13 is not toxic at the standard physiological  
concentration, 	 with 	 the 	 increased 
concentration present in Alzheimer's, it causes 
neuronal degeneration. However, all processes 
that cause increased APP levels and therefore 
A13 levels are not currently known, though 
mutations in the APP gene play a factor in 
genetic cases of AD (Borlongan, 2012). 
A(342 is a longer variant of the Ap peptide, 
which is most susceptible to aggregation, 
which is the process that eventually leads to cell 
death. Instead of forming an a-helix as the 
peptides usually do, they form [3-sheets, which 
come together to form toxic amyloid plaques 
(Jakob-Roetne et al., 2009). The accumulation 
of these plaques then set off a chain of events 
that lead to neuronal dysfunction, inability to 
perform long- term potentiation (a function 
that is critical for memory) and finally 
neurodegeneration (Jakob-Roetne et al., 2009, 
p. 3041). 
Although the buildup of toxic amyloid 
plaques clearly plays an important role in the 
pathology of Alzheimer's, there are also clearly 
other important co-pathologies. The best 
researched among them is the buildup of 
neurofibrillary tangles caused by the over-
phosphorylation of the tau protein (Jakob-
Roetne et al., 2009). However, this is only one 
of the many other observed pathological 
MODERN PSYCHOLOGICAL STUDIES 
	 62 
CHOLINERGIC HYPOTHESIS & STEM CELL TREATMENT I GAUTAM & NICHOLS 
differences in AD and it is not yet known 
which change is the root cause. Because of lack 
of definitive information regarding the initial 
trigger and cause of Alzheimer's, many current 
treatments function as palliative treatments 
and attempt to work to stop the process of 
neurodegeneration not by addressing the 
underlying pathology but instead looking to 
aid and replenish the areas of the brain most 
devastated by neuronal death. Although 
palliative treatments will never constitute a 
permanent cure for Alzheimer's, because of the 
current lack of a permanent cure, they provide 
an important means by which to delay the 
progression of the disease. Even upon the 
eventual discovery of the treatment for the 
underlying pathology of Alzheimer's, it will be 
critical to have palliative treatments available to 
slow the progress of the disease in order to give 
time for the cure to function. 
Cholinergic Hypothesis  
somehow related to the pathophysiology of the 
disease. 
Furthermore, recent longitudinal studies have 
indicated an initial plasticity and subsequent 
loss of plasticity in the cholinergic system. The 
study looked at the levels of choline 
acetyltransferase (ChAT), which is an enzyme 
that facilitates the creation of acetylcholine 
from acetyl-CoA and choline. The results 
showed an increase in ChAT levels in cases of 
mild cognitive impairment and mild AD, but 
normal levels in cases of moderate to severe 
AD. Scientists concluded from this data that 
the brain initially attempts to compensate for 
lower acetylcholine (ACh) levels by 
upregulating ChAT, but that as the disease 
progresses the brain is unable to sustain the 
process of compensation (Frolich, 2002). 
Therefore, palliative treatments that continue 
to compensate for ACh reduction would be 
effective in suppressing the cognitive 
symptoms of AD. 
The most popular palliative treatments for 
Alzheimer's are directed towards the 
cholinergic hypothesis, which posits that a 
significant loss of cholinergic neurons in the 
CNS is a primary contributor to the cognitive 
symptoms of Alzheimer's (Bartus, 2000). The 
treatments directed at this hypothesis, which 
include cholinesterase inhibitors, are one of the 
few current treatments for Alzheimer's that 
have been approved by the FDA. 
There exists much evidence that points to the 
idea that the loss of cholinergic neurons in the 
CNS and particularly in the basal forebrain 
contributes to a loss of cognitive function. 
Since the mid-1990s, studies have shown that 
the severity of degradation of cholinergic 
neurons correlates to the clinical severity of 
Alzheimer's before death, the deposition of 
neurofibrillary tangles and well as amyloid 
plaques (Frolich, 2002). This suggests that the 
amyloid hypothesis and the cholinergic 
hypothesis are connected and that both are 
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Treatments 
Drug treatments 
After the identification of Alzheimer's as a 
disease, the search for a cause and subsequently 
a treatment began. However, since research 
into causes has not led to one distinct answer 
but instead multiple observations about the 
neural systems effected during AD, drug 
treatments of three distinct types were 
developed — drugs that acted as indirect ACh 
agonists and inhibited the action of ACh 
esterases, drugs that block the formation of 
amyloid plaques, and drugs that inhibit 
NMDA receptors (Taupin, 2009). But while 
all the three types of drugs are effective to some 
extent in alleviating the symptoms of 
Alzheimer's, they are unable to stop the 
progress of the disease. 
Gene therapy 
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Alzheimer's has been observed to be 
heritable to an extent, and that has spurred 
research on possible genetic markers. While 
different genes have been associated with 
Alzheimer's, there has not been enough 
research to identify definite genetic causes. 
Therefore, current gene therapy research 
instead focuses on the causes proposed by the 
different hypotheses. One type of gene therapy 
that has been developed recently involves 
genetically modifying cells to produce more 
acetylcholine. Fu et al. (2004) transplanted a 
ChAT overexpression gene in bacteria and 
injected the vector bacteria into mice treated 
with A13 to induce Alzheimer-like cognitive 
deficiencies. The researchers observed that the 
vector bacteria successfully crossed the blood-
brain barrier and post mortem neural analysis 
shows successful expression of the gene in 
some neurons in the brain. The mice treated 
with the bacteria vector also showed improved 
cognitive abilities. In addition to testing gene 
therapy, this study also showed that increasing 
ChAT levels in specific areas of the brain could 
help alleviate cognitive deficiencies induced by 
Alzheimer's. 
Other proteins currently being targeted in 
gene therapy are nerve growth factor (NGF) 
and brain-derived neurotrophic factor 
(BDNF). Both of these molecules have been 
associated with synaptic plasticity (Chen et al., 
2012), and NGF has been shown to decrease 
neuronal cell death (Kim, Lee & Kim, 2013). 
Stem-cell treatment. Stem cells are one of the 
most recent treatment options for 
neurodegenerative diseases. The cell death in 
AD is not limited to a specific type of neurons. 
Since stem cells can divide and differentiate 
into a variety of cell types, they seem a 
reasonable solution this widespread neuronal 
cell death. Different groups of researchers have 
independently found that transplantation of 
multipotent stem cells (MSCs) transplanted 
into the brains of rat models of AD led to both  
reduction of A13 deposition and tau 
hyperphosphorylization. Furthermore, this 
treatment also led to improvements in memory 
and spatial learning among the rats (Glat & 
Offen, 2013). 
Additionally, stem cells can be genetically 
modified in order to also counter some of the 
chemical effects of Alzheimer's, like the 
decrease in cholinergic sensitivity. 
Genetic modifications can also increase the 
levels of specific neurotrophic factors by 
increasing production of those molecules. By 
combining stem cell treatment and gene 
therapy through genetic modification of stem 
cells, it is possible to take advantage of both the 
benefits of using stem cells to replace areas of 
prevalent neuronal death as well as the benefits 
of increasing the production of specific 
proteins known to help treat the cognitive 
symptoms of AD. 
Recent research has found that 
transplanting stem cells producing more 
ChAT helped improve working memory in 
mice with lesions imitating neuronal cell death 
in Alzheimer's (Wang et al., 2006; as cited in 
Kim et al., 2013), transplanting cells with 
increased production of NGF improved 
memory in rats (Wu et al., 2006; as cited in 
Kim et al., 2013), and transplanting cells 
producing more BDNF improved working 
memory in mice (Blurton-Jones et al., 2006; as 
cited in Kim et al., 2013). In 2012, Park et al. 
conducted an experiment with rats that were 
injected with kainic acid to induce neuronal 
cell death akin to that in Alzheimer's. Four 
weeks later, neural stem cells (NSCs) 
genetically modified to produce excess of 
ChAT were transplanted in the lesioned areas. 
The rats were tested for learning and memory. 
Over a few weeks, the rats showed full 
restoration of ACh levels in the brain and their 
learning and memory capacities improved to a 
level comparable to normal rats (Glat et al., 
2013, p. 1492). A similar study conducted that 
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same year found that transplanting NSCs 
producing more NGF in mice had similar 
effects as those seen when ChAT 
overexpressing NSCs were implanted (Lee et 
al., 2012; as cited in Kim et al., 2013). 
However, stem cell treatment faces its own 
obstacles. Stem cells have been the center of 
ethical debates for a while now. While the 
human brain does have some amounts of 
naturally occurring NSCs, suggesting that 
inducing neurogenesis in AD patients could be 
a possible cure (Glat et al., 2013), the 
possibility of AD having genetic markers 
diminishes the capacity for these NSC to 
successfully fill in for areas of neuronal death. 
It is possible to take the naturally occurring 
NSCs and genetically modify them, but the 
amount of such NSCs available is still low 
compared to the levels of cell death. 
Umbilical cords have some amounts of 
MSCs, but not a lot of research has used 
umbilical cord MSCs. Stem cells can be 
harvested from embryos but there has been 
much pushback on this subject because of 
issues of ethics. 
A further problem regarding stem cell 
transplant is that it is unpredictable. Since stem 
cells can differentiate into a variety of different 
types of cells, there is no way to fully regulate 
the differentiation process to only form the 
specific subtype or subtypes needed. Recent 
research has focused a lot on generating 
specific subtypes of neurons from stem cells. 
Bissonnette et al. (2011) generated functional 
basal forebrain cholinergic neurons from 
embryonic stem cells with a success rate of 
85%. They also stated that with additional 
controls, the success rate could be increased to 
94%. However, this differentiation was carried 
out in a culture medium and not after 
transplantation. In 2013, Crompton et al. 
carried out successful controlled differentiation 
of transplanted NSCs using sonic hedgehog 
(SHH) signaling, the basic premise being that 
in an embryo the stem cells differentiate into 
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specific neuronal subtypes due to SHH 
signaling. This research suggests that it may be 
possible to take advantage of the chemicals 
involved in SHH signaling to control the 
differentiation of stem cells. 
Once transplanted, it is difficult to ensure 
that the cells travel to the appropriate places 
and form the appropriate neural connections. 
Without the appropriate neural connections, 
the overexpression of chemical factors will not 
be as effective. Though Park et al. (2012) 
found a more than 96% success rate in the 
appropriate migration and differentiation of 
transplanted NSCs, this research was done on 
an animal model and such high success rates 
need to be replicated by multiple studies before 
the treatment can be tried on humans. Some of 
the pathologies associated with AD might be 
affecting the success of proliferation and 
differentiation of transplanted cells. Few 
studies have investigated the effect of A13 on 
transplanted cells and while some showed that 
it hindered proliferation and transplantation 
(Haughey et al, 2002; as cited in Glat et al., 
2013), another study showed that it helps in 
successful proliferation and degradation Gin et 
al., 2004; as cited in Glat et al., 2013), 
suggesting that AP oligomers help in 
proliferation and differentiation, but as the 
disease progresses, the fibrils formed from Ap 
lead to cell death. 
It is additionally possible that if embryonic 
stem cells from a stem cell bank are used, the 
transplanted cells will also be unrecognizable 
to the immune system and therefore may lead 
to an immunological response. Because of this 
complication, researchers have been focused on 
learning to use stem cells found naturally in the 
muscles, or on taking skin cells and inducing 
them to pluripotency, creating induced 
pluripotent stem cells (iPSC). Since these stem 
cells have the same genetic makeup as the rest 
of the body's cells, the body recognizes them as 
its own and therefore no immunological 
i 
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response is elicited. However, the other 
problems of specific differentiation and 
formation of appropriate connections remain. 
Discussion 
The lack of clarity in terms of the causes of 
Alzheimer's has hindered the search for a cure 
till now. Palliative drug treatments have helped 
in alleviating the symptoms of the disease, but 
there is still no cure for AD. While gene 
therapy has had some success on animal 
models, more research is needed on the specific 
functionality of these different proteins and 
how they affect the pathophysiology of AD. 
Furthermore, studies should be done to 
address the potential benefits of combining 
different gene therapies and using them 
together to create a multi-pronged approach to 
treating AD. More research also needs to be 
done on the combination of gene therapy and 
stem cell treatment in Alzheimer's. Of 
particular interest is how different genetic 
changes can be incorporated together to affect 
the same group of stem cells in order to create 
a multi-pronged approach to the treatment of 
Alzheimer's. The idea would be that hopefully 
by combining these smaller scale successes, a 
more long-lasting and overarching treatment 
could be found which could potentially arrest 
the progress of the disease. Despite the 
problems associated with the use of stem cells 
in neurodegenerative diseases, these 
approaches to treating Alzheimer's are 
incredibly promising. The use of stem cells is 
currently the only known method of reversing 
the effects of neuronal death, and when those 
effects are combined with the effects of gene 
therapy using genetically modified cells, there 
is a great potential for a the creation of a 
treatment more effective than anything that is 
currently available. The goal of this new 
treatment would be to create a long-term 
palliative treatment that could arrest the rapid  
advance of Alzheimer's, and possibly add years 
onto the lives of patients. There is still much 
investigation that needs to be done, including 
moving the research from animal models to 
human trials and further experimenting with 
the combination of the different genetic 
alterations. However, the research already 
completed provides a solid foundation that 
shows great potential for the development of a 
new, cutting-edge treatment for Alzheimer's. 
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